12:00 AM
 | 
Mar 04, 2002
 |  BioCentury  |  Strategy

CAT catches a change artist

Cambridge Antibody Technology Group plc has defied conventional wisdom by choosing a new CEO with no experience in moving drugs through the clinic to market. Instead, the antibody company last week named Peter Chambre, who was COO at Celera Genomics Group, because of his expertise in helping companies make the transition from one stage of development to another.

"Both the board and senior company management were unanimous in selecting Peter," said John Aston, CFO at Cambridge Antibody (LSE:CAT; CATG, Melbourn, U.K.). Chambre will start work in early April, when founder and CEO David Chiswell leaves.

"We perceived the personal qualities needed for the transformation of the company into a profitable biopharmaceutical company as leadership and general management skills," said Aston. "Someone with the ability to develop and implement a strategy for the company, to give...

Read the full 656 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >